BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...July IPO, is developing selective inhibitors of SHP-2...
...Protein kinase CRET – Ret proto-oncogeneSHP-2 (SHPTP2; PTPN11...
BioCentury | Dec 21, 2020
Finance

Dec. 21-23 Financial Quick Takes: Venture rounds for SomaLogic, ONL; plus Jacobio’s HK listing, Cullinan, Gracell and Zhaoke file for IPOs, and more

...Qiming Ventures said it is the largest institutional investor. Jacobio’s two clinical programs, which are SHP-2...
...infectious and chronic diseases. TARGETSEGFR (ErbB1; HER1) - Epidermal growth factor receptorSHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 BC...
BioCentury | Dec 17, 2020
Deals

Dec. 16 Quick Takes: MacroGenics' margetuximab approved for breast cancer; plus sotorasib, Mesoblast, Cardior, Takeda, Allero

First approval for MacroGenics FDA approved Margenza margetuximab-cmkb from MacroGenics Inc. (NASDAQ:MGNX) — the company’s first approved drug — to treat metastatic HER2-positive breast cancer patients...
BioCentury | Dec 15, 2020
Deals

Genentech gets competitive in KRAS with early dealmaking push: Data Byte

...agreement that gives Genentech development rights to SHP-2...
...K-Ras) – KRAS proto-oncogeneSHP-2 (SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2 Lauren...
...Inc. KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11...
BioCentury | Dec 5, 2020
Product Development

Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai

Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and other genetic epilepsies. The Cambridge, Mass.-based start-up, which has...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...solid tumor candidate BBP-398. Navire Pharma Inc., another BridgeBio company, is focusing development of the SHP-2...
...tumors and other hard-to-treat cancers. Yu said Navire has already submitted its IND for the SHP-2...
...Editor Sandi Wong contributed to this report.TARGETSFGFR – Fibroblast growth factor receptor  SHP-2 (SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2 Jeff...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...another BridgeBio company. Navire is developing the SHP-2...
...each therapeutic area. This is exemplified with the SHP-2...
...Investors and Wellington Management.TARGETSSHP-2 (SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2 Virginia...
BioCentury | Oct 27, 2020
Product Development

Mirati impresses with KRAS inhibitor response rates, potential biomarker

...4CDK6 – Cyclin-dependent kinase 6EGFR – Epidermal growth factor receptorKRAS (K-Ras) – KRAS proto-oncogeneSHP2 (SHPTP2; PTPN11...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...small molecules for cancer, and has partnered with AbbVie Inc. (NYSE:ABBV) to develop its lead SHP-2...
...IKAROS family zinc finger 1IKZF3 (AIOLOS) - IKAROS family zinc finger 3SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul...
Items per page:
1 - 10 of 2489